Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Innate Pharma
  6. Summary
    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
2.972(c) 2.994(c) 3.116(c) 3.2(c) 3.25(c) Last
162 951 270 332 579 439 341 118 290 208 Volume
-1.26% +0.74% +4.07% +2.70% +1.56% Change
More quotes
Financials
Sales 2021 39,8 M 48,1 M 48,1 M
Net income 2021 -40,6 M -49,2 M -49,2 M
Net Debt 2021 27,3 M 33,0 M 33,0 M
P/E ratio 2021 -2,13x
Yield 2021 -
Sales 2022 86,5 M 105 M 105 M
Net income 2022 -33,1 M -40,1 M -40,1 M
Net Debt 2022 48,8 M 59,1 M 59,1 M
P/E ratio 2022 -6,91x
Yield 2022 -
Capitalization 257 M 310 M 311 M
EV / Sales 2021 7,14x
EV / Sales 2022 3,53x
Nbr of Employees 244
Free-Float 75,2%
More Financials
Company
Innate Pharma is a clinical-stage biotechnology company specialized in immuno-oncology and dedicated to improving cancer treatment through innovative therapeutic antibodies that exploit the immune system. Innate Pharma's broad antibody portfolio includes several potential «first-in-class» candidates in clinical and preclinical stages in cancers with high medical need. Innate Pharma is a pioneer in the understanding... 
Sector
Biotechnology & Medical Research
Calendar
06/22 | 07:00amPresentation
More about the company
Ratings of Innate Pharma
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about INNATE PHARMA
06/10INNATE PHARMA  : Presents New Data on Next-Generation NK Cell Engager Platform a..
PU
06/10Innate Pharma Molecule Shows Anti-Tumor Effect in Preclinical Studies
MT
06/10Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform a..
GL
06/09INNATE PHARMA  : New Lacutamab Data From Tellomak Trial to be Showcased in Oral ..
PU
06/09New Lacutamab Data from TELLOMAK Trial to be Showcased in Oral Presentation a..
GL
06/03INNATE PHARMA  : Assemblee Generale Mixte
PU
05/31NHTHERAGUIX : NH TherAguix and the CHU Grenoble-Alpes announce the publication o..
DJ
05/28INNATE PHARMA  : Outcome of Innate Pharma's Annual General Meeting (Form 6-K)
PU
05/28INNATE PHARMA  : Outcome of Innate Pharma's Annual General Meeting
PU
05/28INNATE PHARMA  : Outcome of Innate Pharma's Annual General Meeting
GL
05/28INNATE PHARMA  : Proxy Statments
CO
05/25INNATE PHARMA  : Monthly statement on outstanding equity shares and voting right..
CO
05/20SEZARY SYNDROME PIPELINE : Emerging Therapies and Key pharma players involved by..
AQ
05/19INNATE PHARMA  : Erratum (English Version)
PU
05/14INNATE PHARMA  : Virtual 2021 Annual General Meeting (Form 6-K)
PU
More news
News in other languages on INNATE PHARMA
06/10Les valeurs à suivre jeudi 10 juin 2021 à Paris -
06/10INNATE PHARMA  : présentera des données Issues de sa plateforme ANKET
06/10INNATE PHARMA  : Presentera des Donnees Issues de sa Plateforme de NK Cell Engag..
06/10INNATE PHARMA  : Presentera des Données Issues de sa Plateforme de NK Cell Engag..
06/09INNATE PHARMA  : De Nouvelles Donnees pour Lacutamab Issues de l'Essai TELLOMAK ..
More news
Analyst Recommendations on INNATE PHARMA
More recommendations
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 6,85 €
Last Close Price 3,25 €
Spread / Highest target 125%
Spread / Average Target 111%
Spread / Lowest Target 96,9%
EPS Revisions
Managers and Directors
NameTitle
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Frederic Lombard Chief Financial Officer
Hervé Eloi Dominique Brailly Chairman-Supervisory Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Odile Belzunce Senior VP-Compliance, IT & Operations
Sector and Competitors
1st jan.Capitalization (M$)
INNATE PHARMA-6.12%310
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.35.87%46 658
CELLTRION, INC.-26.04%32 458
SEAGEN INC.-10.60%28 416